Home Alzheimer’s Disease Nab-Paclitaxel Has Efficacy Equivalent to Standard Docetaxel in Previously Treated NSCLC

Nab-Paclitaxel Has Efficacy Equivalent to Standard Docetaxel in Previously Treated NSCLC

Noninferiority of nab-paclitaxel (Abraxane) compared with docetaxel was confirmed by assessing end points such as progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) for the treatment of previously treated patients with advanced non–small cell lung cancer (NSCLC), according to phase 3 trial results (UMIN000017487) presented virtually at the 2020 World Conference on Lung Cancer Singapore.1

Results from a total of 503 patients were presented by Atsushi Nakamura, MD, PhD, from Sendai Kousei Hospital in Japan. Patients were randomized 1:1 to receive either nab-paclitaxel (n = 252) at 100 mg/m2 on days 1, 8, and 15 every 3 weeks or docetaxel (n = 251) at 60 mg/m2 on day 1 every 3 weeks. Patients were stratified by sex, histology, disease stage, ECOG performance status, number of prior chemotherapies, and previous exposure to immune checkpoint…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Recent Comments